Cancer treatment
AssigneeLDN Pharma Limited
InventorWai Liu
Life of this patent
Estimating the term…
Abstract
The present invention is based on the finding that the inhibition of the proliferation of cancer cells by cannabinoids is brought about more effectively by combined treatment with low dose naltrexone (LDN) or 6-β-naltrexone (6BN), a metabolite of naltrexone. There is provided a pharmaceutical composition comprising naltrexone or a metabolite thereof or an analogue thereof, for use in the treatment of cancer within a subject, wherein a therapeutically effective amount of the naltrexone or metabolite thereof or analogue of either is to be administered to the subject in a first treatment phase, wherein after the first treatment phase the subject is to be administered a therapeutically effective amount of a cannabinoid in a second treatment phase.
Claims16
A method of treating cancer within a subject comprising administering to the subject a pharmaceutical composition comprising:
- naltrexone;
- or
- 6-β-naltrexol, 2-hydroxy-3-methoxy-6β-naltrexol or 2-hydroxy-3 methoxy-naltrexone;
- or
- an analogue selected from the group consisting of methylnaltrexone, naloxone, nalmefene and nalorphine;
- wherein the pharmaceutical composition is administered in a therapeutically effective amount in a first treatment phase, wherein after the first treatment phase the subject is to be administered a therapeutically effective amount of a cannabinoid in a second treatment phase.
A method of treating cancer within a subject, wherein said subject is characterized in having undergone a first treatment phase during which the subject is administered a preparation comprising a therapeutically effective amount of:
- naltrexone;
- or
- 6-β-naltrexol, 2-hydroxy-3-methoxy-6β-naltrexol or 2-hydroxy-3 methoxy-naltrexone;
- or
- an analogue selected from the group consisting of methylnaltrexone, naloxone, nalmefene and nalorphine,
- and wherein following the first treatment phase a therapeutically amount of a cannabinoid is to be administered to the subject in a second treatment phase.
A method of treating cancer within a subject comprising administering to the subject a preparation comprising:
- naltrexone;
- or
- 6-β-naltrexol, 2-hydroxy-3-methoxy-6β-naltrexol or 2-hydroxy-3 methoxy-naltrexone;
- or
- an analogue selected from the group consisting of methylnaltrexone, naloxone, nalmefene and nalorphine,
- and a cannabinoid,
- wherein the naltrexone or 6-β-naltrexol, 2-hydroxy-3-methoxy-6β-naltrexol or 2-hydroxy-3 methoxy-naltrexone or analogue of either is provided in a therapeutically effective amount to be administered in a first treatment phase, wherein the cannabinoid is provided in a therapeutically effective amount to be administered in a second treatment phase following the first treatment phase.
A method for determining the suitability of a subject with cancer for treatment with a cannabinoid in a second treatment phase, said subject having undergone a first treatment phase with a composition or preparation comprising:
- naltrexone;
- or
- 6-β-naltrexol, 2-hydroxy-3-methoxy-6β-naltrexol or 2-hydroxy-3 methoxy-naltrexone;
- or
- an analogue selected from the group consisting of methylnaltrexone, naloxone, nalmefene and nalorphine,
- the method comprising the steps of:
- i. contacting a sample obtained from the subject after or during a recovery phase with a probe specific for CB2;
- ii. determining the concentration of CB2 within the sample;
- and
- iii. comparing the concentration of CB2 within the sample with a concentration of CB2 determined from a sample obtained from the subject before the first treatment phase,
- wherein if the CB2 concentration has increased by at least two-fold after first treatment phase, the subject is suitable for the second treatment phase.
Dependencies are inferred from the claim text.